No Data
US Manufacturing Index Rises To 43, Highest Since 2020
Aquestive Therapeutics: Strong Buy Rating Driven by Robust Revenue Performance and Strategic Positioning in Allergy Treatment
Aquestive Therapeutics Advances Drug Candidates Amid Challenges
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $10
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
Promising Future and Strategic Advancements: Buy Recommendation for Aquestive Therapeutics
No Data
No Data
